CTRI/2018/05/013637已完成1 期
A Single Centre, Open label, Single Arm, Phase I Study to evaluate the Tolerability, Safety and Immunogenicity of a 15-Valent Pneumococcal Conjugate Vaccine (PCV15) in healthy subjects between 18-45 years of age - 15-Valent Pneumococcal Conjugate Vaccine (PCV15)
Tergene Biotech Pvt Ltd A Joint Venture of Aurobindo Pharma Ltd0 个研究点目标入组 29 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 29
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Healthy subjects between 18 to 45 years of age both inclusive
- •2.Subjects having no clinically significant findings on physical examination and clinical laboratory tests
- •3.Eligibility for the study would be determined by medical history physical examination screening laboratory tests and PIs clinical judgment Subjects with preexisting stable disease defined as disease not requiring significant change in therapy or hospitalization for worsening disease within 12 weeks before receipt of study vaccine are eligible
- •4.Subjects not currently participating in any other clinical trials and not having a plan of taking additional pneumococcal vaccines licensed or investigational as well as other non-study vaccines throughout study duration
- •5. The subject must be able to understand and provide the ICF If subject is not literate an Impartial Witness can sign the ICF if the subject understands and is willing to participate in the study
- •6.Subject must be available for the entire study period and willing to adhere to protocol requirements as evidenced by written ICF
- •7.Subjects must have negative test results for HIV 1 2 HCV and HBsAg
排除标准
- •1.Incapable of understanding the ICF
- •2.Previous vaccination with licensed or investigational pneumococcal vaccine
- •3.Received any vaccine within 30 days before the study vaccine except influenza vaccine
- •4.Females who are pregnant breastfeeding or planning a pregnancy or who are of childbearing potential and not using a reliable method of contraception throughout study duration
- •5.Receipt of blood products or gamma globulin including Hepatitis B immunoglobulin and any monoclonal antibody within 6 months before study vaccination or anticipated receipt of such before study completion
- •6.Receipt of diphtheria or diphtheria-containing vaccine within 6 months before study vaccine administration or anticipated receipt of diphtheria-containing vaccine before study completion
- •7.History of any S. pneumoniae infections
- •8.Known hypersensitivity to any component of the vaccine, including diphtheria toxoid
- •9.Subjects with thrombocytopenia or any coagulation disorder or to those receiving anticoagulant therapy
- •10.Subjects with an acute or chronic condition eg metastatic malignancy severe chronic obstructive pulmonary disease requiring supplemental oxygen end stage renal disease with or without dialysis clinically unstable cardiac disease that in the Investigators opinion would limit the subjects ability to complete or participate in this clinical trial
- •11.Subjects with acute disease at the time of enrollment defined as presence of a moderate or severe illness with or without fever Oral temperature 38°C
- •12.Subjects with a history of Splenectomy
- •13.Subjects with known/suspected immunosuppressive or immunodeficient condition, or receiving immunosuppressive therapy Subjects having received systemic corticosteroids for short term treatment of acute illness would be eligible to receive vaccine 1 month after discontinuation of corticosteroid therapy
- •14.Subjects with any sign or symptom of systemic dysfunction especially of the central nervous system CNS
- •15.Any criteria which in the opinion of the Investigator, suggests that the subject would not be compliant with the study protocol or would confound the result of the study
- •16. Subjects unable to receive vaccination in the deltoid muscle of either arm due to low muscle mass
研究者
相似试验
已完成
1 期
A phase I single ascending dose (SAD) study to investigate the safety, tolerability and pharmacokinetics of oral Capromorelin in spinal cord injury (SCI) and able-bodied volunteersAlleviating the effects of autonomic dysfunction following spinal cord injury.Neurological - Other neurological disordersInjuries and Accidents - Other injuries and accidentsACTRN12614001122640niversity of Melbourne20
尚未招募
1 期
A clinical trial to study the effects of DWRX2003 (Niclosamide IM Depot Injection) in COVID-19 patientsCTRI/2021/07/034522Daewoong Pharmaceutical India Pvt Ltd
招募中
不适用
phase 1/2a clinical study to evaluate the safety and exploratory efficacy for PSA-NCAM (+) NPCInjury, poisoning and certain other consequences of external causesKCT0005628S.Biomedics5
招募中
不适用
A Study on the Evaluation of the Safety and Effectiveness of Autologous activated lymphocyte Injection in Stage 4 Solid Cancer Patient.NeoplasmsKCT0006567Gsamhospital240
进行中（未招募）
1 期
A study of the effect of hydrogen peroxide foam in patients with bacterial vaginosisMedDRA version: 18.1Level: PTClassification code 10004055Term: Bacterial vaginosisSystem Organ Class: 10021881 - Infections and infestationsBacterial vaginosisEUCTR2015-003356-51-SEZelmic AB30